SCHEMBL5429264

SCHEMBL5429264

Cc1ccc(C(=O)NC2CCCCCC2)cn1

nearest known ligand 0.65

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.65
RAB9A P51151 3/20 0.65
HPGD P15428 2/20 0.65
CYP1A2 P05177 1/20 0.65
CYP2C19 P33261 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
GRM5 P41594 3/20 0.57
HDAC1 Q13547 1/20 0.57
HDAC6 Q9UBN7 1/20 0.57
ALDH1A1 P00352 1/20 0.55
TSHR P16473 1/20 0.55
KMT2A Q03164 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5429612 1.00 NPC1 (0.65) NPC1RAB9AHPGDCYP1A2CYP2C19
SCHEMBL5424850 0.98 NPC1 (0.62) NPC1RAB9AHPGDCYP1A2CYP2C19
SCHEMBL5428549 0.95 HDAC1 (0.58) NPC1RAB9AHPGDCYP1A2CYP2C19
SCHEMBL5427032 0.92 HDAC1 (0.62) NPC1RAB9AHPGDCYP1A2CYP2C19
SCHEMBL5422098 0.87 GRM5 (0.60) NPC1RAB9AHPGDCYP1A2CYP2C19
SCHEMBL21489956 0.85 SMYD3 (0.59) HDAC1HDAC6
SCHEMBL19701357 0.85 SMYD3 (0.59) HDAC1HDAC6
SCHEMBL26944377 0.84 HDAC6 (0.53) HDAC1HDAC6KMT2A
SCHEMBL7239293 0.83 GRM5 (0.59) NPC1RAB9AHPGDCYP1A2CYP2C19
SCHEMBL26804453 0.83 SMYD3 (0.63) NPC1RAB9AHPGDCYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-08 US claimed
EP-1551404-A2 METHOD OF INHIBITING ANGIOGENESIS Abbott Laboratories (US) 2005-07-13 EP claimed
US-20040116479-A1 Method of inhibiting angiogenesis ABBOTT LABORATORIES 2004-06-17 US claimed
WO-2004032908-A9 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LAB (US) 2004-05-27 WO claimed
WO-2004032908-A2 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LABORATORIES (US) 2004-04-22 WO claimed
US-20040067985-A1 Method of inhibiting angiogenesis ABBOT LABORATORIES 2004-04-08 US claimed
US-20070043089-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-22 US disclosed
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-08 US disclosed
EP-1551404-A2 METHOD OF INHIBITING ANGIOGENESIS Abbott Laboratories (US) 2005-07-13 EP disclosed
US-20040116479-A1 Method of inhibiting angiogenesis ABBOTT LABORATORIES 2004-06-17 US disclosed
WO-2004032908-A9 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LAB (US) 2004-05-27 WO disclosed
WO-2004032908-A2 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LABORATORIES (US) 2004-04-22 WO disclosed
US-20040067985-A1 Method of inhibiting angiogenesis ABBOT LABORATORIES 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS PGF, VEGFA, FLT4 NPC1 1651/4885RAB9A 2668/4885HPGD 158/4885
US-20070043089-A1 METHOD OF INHIBITING ANGIOGENESIS PGF, VEGFA, FLT4 NPC1 1651/4885RAB9A 2668/4885HPGD 158/4885
US-20040067985-A1 Method of inhibiting angiogenesis VEGFA, PGF, FLT4 NPC1 1172/4885RAB9A 2825/4885HPGD 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.